Prescription medicines: applications under evaluation

21 June 2022 - The TGA has updated its list of applications for new medicines or new uses for existing ...

Read more →

Former FDA officials call for more transparency for drug approvals

15 June 2022 - The US FDA needs to take a more proactive approach in combatting misinformation and communicating decisions to ...

Read more →

Updated price disclosure guidelines, price disclosure webpages and price disclosure dispute resolution process

8 June 2022 - Amendments made to the National Health Act 1953 and National Health (Pharmaceutical Benefits) Regulations 2017 by the ...

Read more →

2022 April cycle - brand price reductions and savings to patients

31 March 2022 - Brand price reductions and savings to patients resulting from the 2022 April cycle of price disclosure have ...

Read more →

1 April 2022 price disclosure confirmed prices

15 March 2022 - Confirmed 1 April 2022 prices resulting from the 2022 April cycle of price disclosure have now been ...

Read more →

Pūahoaho: clarity around PHARMACs priority lists

9 March 2022 - PHARMAC has released up to date information about its priority lists, including a list of ...

Read more →

COVID-19 vaccines: individual patient data should be submitted to the European Medicines Agency

24 February 2022 - An interesting letter to the Editor of the BMJ from the Head of Drug Assessment at ...

Read more →

Assessment of public opinion on transparency at the US Food and Drug Administration

18 February 2022 - Historically, the US FDA has considered much of the oversight of clinical trials, interactions with companies, and ...

Read more →

Do federal price transparency regulations neglect oncology patients?

24 January 2022 - The National Cancer Institute has identified measuring, understanding, and addressing cancer-related patient financial hardship as a top ...

Read more →

2022 April price disclosure cycle – indicative prices

27 January 2022 - Indicative 1 April 2022 prices resulting from the 2022 April Cycle of Price Disclosure have now been ...

Read more →

COVID-19 vaccines and treatments: we must have raw data, now

19 January 2022 - Data should be fully and immediately available for public scrutiny ...

Read more →

Price disclosure 2022 April cycle outcomes summary

10 December 2021 - The summary of price disclosure price reductions for the 2022 April Cycle has now been published ...

Read more →

1 October 2021 price disclosure confirmed prices

13 September 2021 - Confirmed 1 October 2021 prices resulting from the 2021 October cycle of price disclosure have now been ...

Read more →

Optimising the data available via Health Canada’s clinical information portal

23 August 2021 - Through its Public Release of Clinical Information initiative, Health Canada has provided public access to a vast ...

Read more →

PHARMAC must explain funding decisions

16 August 2021 - “A report this morning that all PHARMAC staff, rather than clinical experts or those with patient ...

Read more →